Journal of Clinical Oncology, Vol 20, Issue 20
(October), 2002: 4232-4241
© 2002 American Society for Clinical Oncology
Comparative Detection of Lymph Node Micrometastases of Stage II Colorectal Cancer by Reverse Transcriptase Polymerase Chain Reaction and Immunohistochemistry
By Shingo Noura,
Hirofumi Yamamoto,
Tadashi Ohnishi,
Norikazu Masuda,
Takashi Matsumoto,
Osamu Takayama,
Hiroki Fukunaga,
Yasuhiro Miyake,
Masakazu Ikenaga,
Masataka Ikeda,
Mitsugu Sekimoto,
Nariaki Matsuura,
Morito Monden
From the Department of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University; and Department of Pathology, School of Allied Health Science, Faculty of Medicine, Osaka University, Osaka, Japan.
Address reprint requests to Hirofumi Yamamoto, MD, PhD, Department of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita City, Osaka 565-0871, Japan; email: kobunyam{at}surg2.med.osaka-u.ac.jp
PURPOSE: Inconsistent conclusions have been drawn about the clinical significance of micrometastases in lymph nodes (LNs) of node-negative colorectal cancer (CRC) patients. We performed a comparative study of detection of micrometastases using immunohistochemistry (IHC) by anti-cytokeratin antibody and carcinoembryonic antigen (CEA)-specific reverse-transcriptase polymerase chain reaction (RT-PCR) in the same patients, in an attempt to move closer to their clinical application.
PATIENTS AND METHODS: Sixty-four CRC patients, with RNA of good quality available from paraffin-embedded LN specimens, were selected from 84 stage II patients who underwent curative surgery between 1988 and 1996. We investigated associations between the presence of micrometastases by each method and prognosis.
RESULTS: Micrometastases were detected in 19 (29.6%) of 64 patients by RT-PCR and in 35 (54.7%) of 64 patients by IHC. By RT-PCR analysis, patients exhibiting a positive band for CEA mRNA had a significantly worse prognosis than those who were RT-PCRnegative, with respect to both disease-free and overall survival (P = .027 and .015, respectively). By IHC analysis, the presence of micrometastasis did not predict patient outcome in terms of either disease-free or overall survival. Infiltrating pattern of tumor growth characteristic was significantly associated with shorter disease-free survival among various clinical or pathologic factors. By multivariate Cox regression analysis, micrometastasis detected by RT-PCR and the Crohns-like lymphoid reaction were both independent prognostic factors.
CONCLUSION: Micrometastases detected by RT-PCR, but not IHC, may be of clinical value in identifying patients who may be at high risk for recurrence of CRC and who are therefore likely to benefit from systemic adjuvant therapy.
The first two authors contributed equally to this study.
This article has been cited by other articles:

|
 |

|
 |
 
Y. Jiang, G. Casey, I. C. Lavery, Y. Zhang, D. Talantov, M. Martin-McGreevy, M. Skacel, E. Manilich, A. Mazumder, D. Atkins, et al.
Development of a Clinically Feasible Molecular Assay to Predict Recurrence of Stage II Colon Cancer
J. Mol. Diagn.,
July 1, 2008;
10(4):
346 - 354.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. R. Turner, C. Li, and C. C. Compton
Newer Pathologic Assessment Techniques for Colorectal Carcinoma
Clin. Cancer Res.,
November 15, 2007;
13(22):
6871s - 6876s.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. G. Nicastri, J. T. Doucette, T. E. Godfrey, and S. J. Hughes
Is Occult Lymph Node Disease in Colorectal Cancer Patients Clinically Significant?: A Review of the Relevant Literature
J. Mol. Diagn.,
November 1, 2007;
9(5):
563 - 571.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Tsujino, I. Seshimo, H. Yamamoto, C. Y. Ngan, K. Ezumi, I. Takemasa, M. Ikeda, M. Sekimoto, N. Matsuura, and M. Monden
Stromal Myofibroblasts Predict Disease Recurrence for Colorectal Cancer
Clin. Cancer Res.,
April 1, 2007;
13(7):
2082 - 2090.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Iddings, A. Ahmad, D. Elashoff, and A. Bilchik
The Prognostic Effect of Micrometastases in Previously Staged Lymph Node Negative (N0) Colorectal Carcinoma: A Meta-analysis
Ann. Surg. Oncol.,
November 1, 2006;
13(11):
1386 - 1392.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Pocard, M. Van den Eynde, D. Goere, V. Boige, and D. Malka
Sentinel Lymph Node Sampling and Analysis in Colon Cancer: What Is the Question?
J. Clin. Oncol.,
August 1, 2006;
24(22):
3712 - 3713.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Seki, H. Yamamoto, C. Yee Ngan, M. Yasui, N. Tomita, K. Kitani, I. Takemasa, M. Ikeda, M. Sekimoto, N. Matsuura, et al.
Construction of a novel DNA decoy that inhibits the oncogenic {beta}-catenin/T-cell factor pathway.
Mol. Cancer Ther.,
April 1, 2006;
5(4):
985 - 994.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Xi, W. Gooding, K. McCarty, T. E. Godfrey, and S. J. Hughes
Identification of mRNA markers for molecular staging of lymph nodes in colorectal cancer.
Clin. Chem.,
March 1, 2006;
52(3):
520 - 523.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Ohrling, D. Edler, M. Hallstrom, P. Ragnhammar, and H. Blomgren
Detection of Thymidylate Synthase Expression in Lymph Node Metastases of Colorectal Cancer Can Improve the Prognostic Information
J. Clin. Oncol.,
August 20, 2005;
23(24):
5628 - 5634.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. B. Ho, A. Hyslop, R. Albrecht, A. Jacobson, M. Spencer, D. A. Rothenberger, G. A. Niehans, J. D'Cunha, and R. A. Kratzke
Quantification of Colorectal Cancer Micrometastases in Lymph Nodes by Nested and Real-Time Reverse Transcriptase-PCR Analysis for Carcinoembryonic Antigen
Clin. Cancer Res.,
September 1, 2004;
10(17):
5777 - 5784.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Wang, T. Jatkoe, Y. Zhang, M. G. Mutch, D. Talantov, J. Jiang, H. L. McLeod, and D. Atkins
Gene Expression Profiles and Molecular Markers To Predict Recurrence of Dukes' B Colon Cancer
J. Clin. Oncol.,
May 1, 2004;
22(9):
1564 - 1571.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. S. Doekhie, K. C. M. J. Peeters, R. A. E. M. Tollenaar, and C. J. H. van de Velde
Minimal Residual Disease Assessment in Sentinel Nodes of Breast and Gastrointestinal Cancer: A Plea for Standardization
Ann. Surg. Oncol.,
March 1, 2004;
11(3_suppl):
236S - 241S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Mori, Y. Fujiwara, Y. Sugita, T. Azama, T. Ishii, K. Taniguchi, K. Yamazaki, S. Takiguchi, T. Yasuda, M. Yano, et al.
Application of Molecular Diagnosis for Detection of Peritoneal Micrometastasis and Evaluation of Preoperative Chemotherapy in Advanced Gastric Carcinoma
Ann. Surg. Oncol.,
January 1, 2004;
11(1):
14 - 20.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. T. Kuo, D. S.B. Hoon, H. Takeuchi, R. Turner, H.-J. Wang, D. L. Morton, and B. Taback
Prediction of Disease Outcome in Melanoma Patients by Molecular Analysis of Paraffin-Embedded Sentinel Lymph Nodes
J. Clin. Oncol.,
October 1, 2003;
21(19):
3566 - 3572.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. F. Shariat, M. P. Roudier, G. E. Wilcox, M. W. Kattan, P. T. Scardino, R. L. Vessella, S. Erdamar, C. Nguyen, T. M. Wheeler, and K. M. Slawin
Comparison of Immunohistochemistry with Reverse Transcription-PCR for the Detection of Micrometastatic Prostate Cancer in Lymph Nodes
Cancer Res.,
August 1, 2003;
63(15):
4662 - 4670.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|